Besivance (besifloxacin HCl)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Besifloxacin is a fluoroquinolone anti-infective agent.
Besifloxacin is a fluoroquinolone anti-infective agent. Besifloxacin is an 8-chloro fluoroquinolone with an N-1 cyclopropyl group. Like other fluoroquinolone anti-infective agents, besifloxacin inhibits DNA synthesis in susceptible organisms via inhibition of DNA topoisomerases (DNA gyrase, topoisomerase IV).
Besifloxacin is active in vitro and in vivo in conjunctival infections against Aerococcus viridans, CDC coryneform group G, Corynebacterium pseudodiphtheriticum, C. striatum, Haemophilus influenzae, Moraxella catarrhalis, M. lacunata, Pseudomonas aeruginosa, Staphylococcus aureus, S. epidermidis, S. hominis, S. lugdunensis, S. warneri, Streptococcus mitis group, S. oralis, S. pneumoniae, and S. salivarius.
Bacteria resistant to besifloxacin have been produced in vitro. Cross-resistance between besifloxacin and some other fluoroquinolones has been reported.
For the topical treatment of conjunctivitis caused by susceptible bacteria, besifloxacin hydrochloride is commercially available as an isotonic ophthalmic suspension containing 6 mg of besifloxacin per mL. Besifloxacin 0.6% ophthalmic suspension has an osmolality of 290 mOsm/kg and contains benzalkonium chloride as a preservative.
Following topical ophthalmic application of besifloxacin 0.6% ophthalmic suspension (3 times daily in both eyes for 16 doses) in adults with suspected bacterial conjunctivitis, maximum plasma concentrations of besifloxacin were less than 1.3 ng/mL and mean peak plasma concentrations were 0.37 or 0.43 ng/mL on days 1 or 6, respectively. Following multiple topical ophthalmic doses, the average plasma elimination half-life of systemically absorbed drug was estimated to be 7 hours.
USES: This medication is used to treat bacterial eye infections. Besifloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria.
This medication treats only bacterial eye infections. It will not work for other types of eye infections. Using any antibiotic when it is not needed can cause it to not work for future infections.
Generic name: besifloxacin HCl
Pronunciation: (BE-si-FLOX-a-sin)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Besivance
Indications
The following indications are listed for Besivance:
- Bacterial Conjunctivitis
Also known as: Inflammation Of The Conjunctiva Due To Bacteria.
Dosing
Besifloxacin is commercially available for topical ophthalmic administration as besifloxacin hydrochloride; dosage is expressed in terms of besifloxacin.
No dosing information is available for this tab.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
No formal drug interaction studies have been performed with besifloxacin 0.6% ophthalmic suspension.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
The manufacturer states that there are no known contraindications to besifloxacin 0.6% ophthalmic suspension.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Conjunctival redness.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
Safety and efficacy of besifloxacin 0.6% ophthalmic suspension have not been established in children younger than 1 year of age.
Although systemic quinolones have been associated with arthropathy in immature animals, there is no evidence that ophthalmic administration of quinolones has any effect on weight bearing joints.
Category C. (See Users Guide.)
Data are not available regarding use of besifloxacin 0.6% ophthalmic suspension in pregnant women.
In animal studies using oral besifloxacin dosages up to 1 g/kg daily, there was no evidence of visceral or skeletal malformations in offspring, but this dosage was associated with maternal toxicity and mortality, increased postimplantation loss, decreased fetal body weights, and decreased fetal ossification.
Although besifloxacin has not been measured in human milk, the manufacturer states that it is presumed that the drug is distributed into human milk.
Caution is advised if besifloxacin ophthalmic suspension is used in nursing women.
No overall differences in safety and efficacy of besifloxacin 0.6% ophthalmic suspension have been observed between geriatric and younger adults.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.